A model for how HS might be subdivided may be found in recent experiences of investigators in characterizing psoriasis. In fact, not all psoriasis is the same; we now recognize several distinct subtypes, based on clinical phenotype, demographics, genetic predisposition, and response to treatment. For example, guttate psoriasis is composed of multiple small plaques on the trunk of young people of the HLA Cw0602 genotype, and it commonly responds well to phototherapy. Personalized medicine projects are now in progress to match more precisely psoriasis genotypes with clinical phenotypes and treatment responses, including the pharmacogenetics of systemic therapy.
HS (also known as acne inversa) research is running to catch up, and increasing awareness indicates that there is phenotypic heterogeneity within the disease spectrum. Common to all HS patients are recurrent, painful nodules, papules, and/or abscesses of apocrine gland-bearing sites, in particular the groin and axilla. ''Typical'' European HS patients have lesions that are restricted largely to these sites, but ''atypical'' HS includes lesions that are more widespread. In this issue, Canoui-Poitrine et al. (2013) have provided a helpful step by meticulously phenotyping 648 patients with HS. LC analysis, with no a priori hypotheses, was used to subdivide the HS clinical phenotype into three groups, based on affected skin sites, lesion types, family history, and associations with (severe) acne. ''Axillary-mammary'' (LC1) HS corresponded to the ''typical'' phenotype seen in European populations. ''Follicular'' (LC2) HS was characterized by comedones, other follicular lesions, and severe acne, whereas the ''gluteal'' (LC3) HS had a predilection for the buttocks.
Utility of the proposed classification
The study by Canoui-Poitrine et al. (2013) has several strengths, including the large size of the patient population and very little missing data. External generalizations are probably limited to
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European secondary-care centers because of the recruitment of patients from specialist clinics. Reasonable face validity was confirmed by clustering of the associated demographic data such that, compared with the ''axillarymammary'' class, ''follicular'' patients were more likely to be male, current smokers, and have more severe disease. A number of the demographic associations fit with preexisting observations, for example, males were less likely to have inframammary disease. As the authors point out, validation studies using other patient populations are now needed.
Nomenclature has been a difficult problem in HS research, exemplified by the lack of universal agreement regarding the condition's name and disease definition. Division of HS into a ''typical'' European ''axillary-mammary'' phenotype, with disease restricted to axillary, inframammary, and groin flexural sites, and an ''atypical'' group provides a relatively clear distinction on the basis of whether nonflexural sites are involved. There will probably be some debate regarding the subclassification of the atypical group into ''follicular'' and ''gluteal''. In particular, the conditional probability of gluteal involvement was only 54% in the ''gluteal'' group, meaning that half of this group did not have gluteal involvement. Furthermore, onethird of the ''follicular'' group did exhibit gluteal involvement. In this context, it may be prudent to consider renaming the ''gluteal'' phenotype. One option would be to focus on absent features. For example, the ''gluteal'' group lacked hypertrophic scars and epidermal cysts.
Genotype-phenotype correlation
The data provided by Canoui-Poitrine et al. (2013) confirm that about onethird of HS patients report a family history of the condition. An autosomal dominant pattern of inheritance was reported 25 years ago, and, in 2010, a Chinese group demonstrated underlying pathogenic mutations in NCSTN, one of the six genes encoding the g-secretase transmembrane complex (Wang et al., 2010) . The Han Chinese HS patients concerned were members of six families with a relatively severe HS phenotype, including extensive involvement et al., 2011; Liu et al., 2011; Pink et al., 2011 Pink et al., , 2012 Miskinyte et al., 2012; Nomura et al., 2012; Zhang et al., 2012) . However, none of the 20 consecutive HS patients seen in a tertiary UK setting were found to have pathogenic g-secretase mutations, including 12 patients who reported a family history of HS (Ingram et al., 2012) . It is possible that unrecognized mutations in genes further down the g-secretaseNotch signaling pathway may be responsible (Melnik and Plewig, 2012) . One of the potential applications of the phenotypic HS subtypes generated by Canoui-Poitrine et al. (2013) is in the field of genotype-phenotype correlation. It is difficult to correlate individual gsecretase mutations with the corresponding phenotypic subtype because of a lack of complete phenotypic data in many reports. Nevertheless, Table 1 summarizes the available phenotypic information, in some cases relying in part on interpretations from clinical photographs, and it details the corresponding g-secretase mutation. All of the mutations appear to correlate with atypical HS, and most are probably best placed in the LC2 ''follicular'' subgroup, because of the involvement of atypical body sites and the presence of hypertrophic scarring. Of the 20 HS patients without pathogenic g-secretase mutations, the majority had a ''typical'' HS phenotype, and probably only three exhibited features of the ''follicular '' subgroup (Ingram et al., 2012) .
Minimum HS phenotype data set?
Difficulties encountered when trying to determine the phenotypic subgroups of HS patients in genetic studies reinforce the need for a minimum HS phenotype data set for future studies. This would be best determined through formal ''consensus'' methods, but one suggestion can be found in Table 2 . Nearly all of these elements were included in the study by Canoui-Poitrine et al. (2013) , except for a patient-reported disease severity measure in the form of quality of life scores.
Translational value for clinical practice
For patients, perhaps the most important element of a classification system would be its predictive validity. Obviously, it is not yet known whether using the proposed system to stratify clinical trials would help to distinguish responders from nonresponders to a specific treatment modality. Another important unanswered question would be whether there are phenotypic predictors of severe disease that might justify early treatment to arrest disease progression and to prevent subsequent scarring and reduced quality of life.
The focus on accurate HS phenotyping provided by Canoui-Poitrine et al. (2013) is an essential step in determining potential genotype-phenotype correlations within the HS disease spectrum, and it permits a better understanding of HS etiology. For patients, ultimately, it may allow a more personalized approach to therapy.
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Clinical Implications
Recognition that hidradenitis suppurativa (HS) is heterogeneous allows more accurate genotype-phenotype correlation studies, and it may help investigators to stratify clinical trials.
Latent class (LC) analysis of a European patient population was used to differentiate HS restricted to ''typical'' sites from ''atypical'' HS, which includes additional skin sites.
Atypical HS was subdivided further into two categories, based on the nature and location of lesions, which now requires further validation. 
